27 Jun, 2017

Somahlution Announces Medical University of Vienna as First Austrian Site to Participate in DuraGraft Registry

27 Jun, 2017

JUPITER, FL May. 5, 2017 — Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, announces today the Medical University of Vienna has started participation to evaluate the company’s flagship product DuraGraft®, a vascular...

Read more
27 Jun, 2017

Somahlution Announces DuraGraft Registry Initiation at Leading Cardiac Surgery Hospitals in Germany

27 Jun, 2017

JUPITER, Fl.- Somahlution announces the first German patient enrolled in its DuraGraft® European Registry clinical trial. The patient was treated by Dr. Prof. Herbert Vetter, Chief Physician at Helios Hospital Wuppertal. Patient enrollment has also begun at the Helios Heart Center Leipzig by Prof. Martin Misfeld, M.D., Ph.D. Somahlution is a...

Read more